Poverty, Healthcare and Human Development · indicator 303
Jan Aushadhi generic-medicine outlets
Modi aheadStore counts for a single national programme. No comparator country publishes an equivalent series, so no synthetic counterfactual can be estimated. The verdict here compares observed Indian figures over time — a weaker basis than the estimated indicators.
2014
80.00
baseline
2026
20,149
latest observed
Change
+25086%
2014 vs latest observed
What this measures
Jan Aushadhi generic-medicine outlets, in kendras. A rising number is an improvement. Reported by Department of Pharmaceuticals — PMBJP.
It stood at 80.00 in 2014, and under Modi’s current India reached 20,149 by 2026 — a rise of 25086%. That is an improvement against India’s pre-2014 figure.
No comparison country reports an equivalent series, so there is no Rahul's India to compare against. This is a before-and-after reading, not a treatment effect.
Decade totals
kendras · Department of Pharmaceuticals — PMBJP
Why no counterfactual
Store counts for a single national programme. No comparator country publishes an equivalent series, so no synthetic counterfactual can be estimated.
Observation quality
- 2014
- 80.00
- 2024
- 20,149
- 2026
- 20,149
Administrative or programme reporting, not a survey measure · 2014
Administrative or programme reporting, not a survey measure · June 2026
Administrative or programme reporting, not a survey measure · 30 June 2026
Outlets selling unbranded generics at a capped price — a maximum of half the average price of the top three branded equivalents. The scheme was launched in November 2008 and had reached 80 outlets by 2014; it was relaunched as PMBJP in 2015. Outlet count is a measure of reach, not of what households actually pay.
The counterfactual is 'India without the 2014 structural break', estimated from comparator countries. It is not a forecast of any individual's policies.